Key statistics
On Friday, AnaptysBio Inc (ANAB:NSQ) closed at 38.48, -6.85% below its 52-week high of 41.31, set on Aug 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 37.60 |
---|---|
High | 39.12 |
Low | 37.10 |
Bid | 31.00 |
Offer | 41.37 |
Previous close | 37.53 |
Average volume | 296.78k |
---|---|
Shares outstanding | 30.18m |
Free float | 29.66m |
P/E (TTM) | -- |
Market cap | 1.16bn USD |
EPS (TTM) | -6.34 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Anaptys Announces Participation in September Investor Conferences
- Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
- Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
- Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
- Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
- Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
- Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
- Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
- Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
More ▼